Navigation Links
Elsevier Announces 2012 Journal Impact Factor Highlights
Date:7/15/2013

ors increased. The Lancet rose from 38.278 to 39.060, The Lancet Oncology saw an increase from 22.589 to 25.117 moving up its subject category ranking from 4th to 3rd position. The Lancet Neurology increased to 23.917, from 23.462, and The Lancet Infectious Diseases went up from 17.391 to 19.966, both journals maintaining the top rankings in their respective categories.

The journals of Cell Press, an imprint of Elsevier, mostly saw quite stable trends in Impact Factor, with highlights including strong growth from Molecular Cell - an 8% increase to 15.280 and Trends in Cognitive Sciences, which saw a 27% increase in comparison to 2011, to 16.008. Its flagship journal Cell continues to lead in its field with an impact factor of 31.957, and is the number one research journal in the Cell Biology and Biochemistry & Molecular Biology categories.

Of the 420 titles in the JCR that Elsevier publishes on behalf of societies, 261, or 62%, showed a rise in their Impact Factors. Nine of these rank number one in their subject categories, among which Evolution and Human Behavior, rising from the 4th position in the category "Social Sciences, Biomedical". Two society journals reached a number one position for the first time: European Urology reached the number one position in "Urology & Nephrology, and Forensic Science International: Genetics ranked highest in the category: "Medicine, Legal".

The Impact Factor helps evaluate a journal's impact compared to others in the same field by measuring the frequency with which recent articles in a journal have been cited in a particular year: the 2012 Impact Factor takes into account citations in 2012 to papers published in 2010 and 2011.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and servic
'/>"/>

SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
4. Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
7. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
8. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
9. Elsevier/Gold Standard Exclusive Publisher of New Predictive Drug Price Type
10. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
11. Elsevier Launches New Journal: Learning, Culture and Social Interaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/57b5qj/global_pdt ... "Global PDT Machine Industry Report 2014" report ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The Global PDT ... in-depth study on the current state of the ... overview of the industry including definitions, classifications, applications ...
(Date:6/1/2015)...  Boston-based Veritas Genetics is launching its mission ... personalized medicine and prevention to the forefront, allowing ... Beginning with its first product, a genetic screen ... Genetics is making its products affordable and accessible, ... genetic data which will be shared with the ...
(Date:6/1/2015)... , June 1, 2015 Esperance Pharmaceuticals ... trial of lead candidate EP-100 in ovarian cancer patients ... designed to seek and destroy cancer cells that overexpress ... receptors are over-expressed in a wide range of cancers. ... Phase II trial of EP-100 were presented at ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global PDT Machine Industry Report 2014 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... July 7 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", the "Company") (Nasdaq: CHBT ... , today provides,further updates on the Company,s bulk additive operation. , ... China-Biotics gained ... and the total number of bulk customers increased to 39 by the ...
... , ... that from a single platform, scientists can efficiently profile lead compounds in their own ... ... -- Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a flexible and complete ...
... CLEVELAND , July 7 DATATRAK International, Inc. ... eClinical solutions for the clinical trials industry, today announced that ... approximately $0.53 per share with certain members of ... sold pursuant to the private placement are restricted securities and ...
Cached Biology Technology:China-Biotics Provides Further Updates on Qingpu New Facility 2China-Biotics Provides Further Updates on Qingpu New Facility 3Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 3
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/25/2015)... market for wearable technologies is considered to be in ... several trials and prototypes. The release of the Apple ... interest in wearables as well as accelerate sales of ... in turn will spur greater innovation from other players ... and distributors. Photo - http://photos.prnewswire.com/prnh/20150526/218287 ...
(Date:5/22/2015)... According to a new market ... Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, ... and Home) - Global Forecast to 2020", published by ... in 2015 to $6.19 Billion by 2020, at a ... data Tables and   43 Figures spread through 140 ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... the word "doctor" to mean "all-knowing," unfortunately, this will ... of medical professionals sometimes leads to devastating misdiagnoses that ... their patients. , But there is hope for better, ... technologies, and one Florida State University researcher is putting ...
... data for E7389 in the treatment of advanced, refractory ... E7389 is a synthetic analog of halichondrin B ... studies to have highly potent anti-cancer activity in vitro ... a type of marine sponge. , This study was ...
... shown that the immune-stimulating hormone known as interleukin-12 ... immune-system protein, as an experimental therapy for some ... to stimulate the immune system to attack certain ... sometimes used to treat melanoma, advanced kidney cancer ...
Cached Biology News:Making medicine 'smarter' 2Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer 2Study shows combination of immune substances to be safe 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
... Single Cell Whole Genome Amplification Kit ... random fragmentation of genomic DNA and ... to PCR-amplifiable library molecules flanked by ... by PCR amplification of the library ...
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Biology Products: